133 completed, 26 unknown, 11 terminated, 8 recruiting. 67 Phase 4, 43 Phase 2, 42 Phase 3, 20 Not applicable, 13 Phase 1.
Follow this drug Literature Review of Latanoprost trials Research Report on Latanoprost
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Measuring the Effects of Netarsudil, Latanoprost, and Combination Therapy on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects Rocklatan (Netarsudil 0.02%/ latanoprost 0.005), Latanoprost (0.005%) - Ocular Hypertension, Suspect Glaucoma | Phase 4 | Recruiting | University of Maryland, Baltimore | 50 | 2026-07-02 | 2026-07-02 |
| Optic Nerve Head Strain in Non-glaucoma Subjects Latanoprost (0.005%) - Glaucoma | Early Phase 1 | Recruiting | Johns Hopkins University | 30 | 2026-06-24 | 2026-07-13 |
| Rocklatan vs Latanoprost Post-DSLT Rocklatan 0.02%-0.005% Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution - Glaucoma | Phase 4 | Recruiting | Eye Centers of Southeast Texas | 36 | 2026-05-14 | 2026-05-22 |
| Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension QLS-111-FDC, Latanoprost (0.005%) - OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension | Phase 2 / Phase 3 | Completed | Qlaris Bio, Inc. | 64 | 2026-03-18 | 2026-07-29 |
| 24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution, Latanoprost 0.005% Ophthalmic Solution - Open Angle Glaucoma, Ocular Hypertension | Phase 4 | Recruiting | Mayo Clinic | 30 | 2025-11-21 | 2026-05-01 |
| A Comparative Study of Intraocular Pressure Control Using Selective Laser Trabeculoplasty and Latanoprost as Initial Treatments for Primary Open Angle Glaucoma and Ocular Hypertension in Lagos State University Teaching Hospital Selective laser trabeculoplasty, Latanoprost (0.005%) - Primary Open Angle Glaucoma or Ocular Hypertension | Not applicable | Recruiting | Lagos State Health Service Commission | 138 | 2025-10-15 | 2025-12-30 |
| Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution, Netarsudil 0.02%/latanoprost 0.005% ophthalmic solution - Ocular Hypertension, Open Angle Glaucoma | Phase 3 | Completed | Alcon Research | 489 | 2025-09-02 | 2026-04-21 |
| Study of Corneal Biomechanics in Glaucoma Patients Using Brillouin Microscopy Prostaglandin Analogue -Containing IOP-Lowering Therapy, Beta Blocker, Brillouin Microscopy - Glaucoma | Recruiting | University of Maryland, Baltimore | 60 | 2025-09-01 | 2026-08-10 | |
| Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension PA5108 Ocular Implant low dose, PA5108 Ocular Implant, high dose, Latanoprost 0.005% Ophthalmic Solution - Glaucoma, Open-Angle, Ocular Hypertension | Phase 2 | Active not recruiting | PolyActiva Pty Ltd | 75 | 2025-05-31 | 2026-07-08 |
| Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost Simbrinza 0.2%-1% Ophthalmic Suspension, Rocklatan 0.02%-0.005% Ophthalmic Solution, Cosopt PF 2%-0.5% Ophthalmic Solution - Open Angle Glaucoma | Phase 4 | Recruiting | Prairie Eye Center | 70 | 2025-05-14 | 2025-05-15 |
| The Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bullous Keratopathy (PBK) Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution, Placebo - Pseudophakic Bullous Keratopathy, Glaucoma | Phase 2 / Phase 3 | Completed | University Hospital Dubrava | 50 | 2025-05-12 | 2026-09-09 |
| A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China DE-117B Eye Drops, Latanoprost - Open Angle Glaucoma, Ocular Hypertension | Phase 3 | Active not recruiting | Santen Pharmaceutical Co., Ltd. | 345 | 2024-11-28 | 2026-05-15 |
| Next Generation Rocklatan AR-17043 Ophthalmic Solution, PG043 Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution - Open Angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | Alcon Research | 426 | 2024-09-04 | 2025-11-18 |
| A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma OMNI Surgical System, Latanoprost plus adjunctive glaucoma medication - Primary Open Angle Glaucoma | Phase 4 | Terminated | Sight Sciences, Inc. | 2 | 2024-08-21 | 2025-01-29 |
| Effect of Latanoprost on Optic Nerve Perfusion Latanoprost (0.005%) - Treatment Outcome | Phase 1 | Completed | Zagazig University | 46 | 2024-06-24 | 2024-10-08 |
| Optic Nerve Perfusion Following Treatment with Latanoprost Versus Brimionidin Tartrate Latanoprost (Xalatan), Brimonidine 0.2 % - Glaucoma | Early Phase 1 | Completed | Zagazig University | 56 | 2024-06-24 | 2024-12-12 |
| How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure? dorzolamide/timolol - Glaucoma, Open-Angle, Glaucoma; Drugs | Phase 4 | Terminated | CT Glaucoma Associates | 36 | 2024-04-22 | 2024-08-23 |
| Latanoprost Eluting Contact Lens for Treating Glaucoma and Ocular Hypertension Latanoprost eluting contact lens, Topical Latanoprost - Glaucoma, Ocular Hypertension | Phase 1 | Terminated | Massachusetts Eye and Ear Infirmary | 1 | 2024-04-03 | 2025-10-15 |
| CHARACTERIZATION OF THE OCULAR SURFACE MICROBIOME IN THE REGION OF EPIRUS AND MACEDONIA (GREECE) Latanoprost with preservatives (BAK) once per day for at least 6 months period - Glaucoma | Active not recruiting | University of Ioannina | 45 | 2024-03-20 | 2026-06-11 | |
| Evaluation of Latanoprost Combined With Fractional Erbium- YAG Laser Latanoprost - Alopecia Areata | Phase 1 / Phase 2 | Unknown | Egymedicalpedia | 70 | 2024-02-01 | 2024-04-16 |
Showing 20 of 186. Sign in to see all of them.
Ocular Hypertension (111) · Glaucoma, Open-Angle (102) · Glaucoma (92) · Hypertension (5) · Alopecia Areata (3) · Eye Diseases (3) · Glaucoma, Angle-Closure (3) · Diabetic Retinopathy (2) · Dry Eye Syndromes (2) · Vitiligo (2) · Alopecia (1) · Aneurysm (1) · Corneal Diseases (1) · Corneal Edema (1) · Exfoliation Syndrome (1)
Alcon Research (25) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (15) · Allergan (10) · Aristotle University Of Thessaloniki (6) · Pfizer (4) · Santen Inc. (4) · Aerie Pharmaceuticals (3) · Bausch & Lomb Incorporated (3) · Nicox Ophthalmics, Inc. (3) · Santen Pharmaceutical Co., Ltd. (3) · Aneira Pharma, Inc. (2) · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (2) · Innovative Medical (2) · Inotek Pharmaceuticals Corporation (2) · Laboratoires Thea (2)
United States (86) · Greece (10) · Italy (10) · France (9) · Canada (8) · Egypt (8) · Denmark (6) · United Kingdom (6) · Germany (5) · South Korea (5) · Spain (5) · Austria (4) · Brazil (4) · China (4) · Japan (4)
Anastasios G Konstas, MD, PhD (2) · Carl B Camras, MD (2) · Luca Rossetti, MD (2) · Luciano Quaranta, MD (2) · Nicox Ophthalmics, Inc. (2) · Osamah Saeedi, MD (2) · Oscar Cuzanni, MD, MSc (2) · Robert Noecker, MD (2) · Robert Ritch, MD (2) · Theresa Landry, Ph.D. (2)
PMID 19427617, PMID 22607109, PMID 17459480, PMID 17686450, PMID 18402717, PMID 20142538, PMID 20181282, PMID 20346127, PMID 20553122, PMID 21399724, PMID 21498617, PMID 21851167, PMID 22332206, PMID 22458918, PMID 22972069, PMID 23420235, PMID 23475405, PMID 23681371, PMID 23881267, PMID 24006861, PMID 24212847, PMID 24855336, PMID 25383466, PMID 25488946, PMID 25533656, PMID 25613811, PMID 25893514, PMID 26756747, PMID 27312975, PMID 27649982, PMID 28617732, PMID 28957960, PMID 32533949, PMID 32884231, PMID 35167779, PMID 35943114, PMID 39477206, PMID 40341017, PMID 40873654, PMID 9261306
2008 (1), 2009 (1), 2015 (1), 2019 (1), R01EY014957 (1), R01EY022124 (1), R01EY036042 (1), R21EY035483 (1)